Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
Sponsor: ADARx Pharmaceuticals, Inc.
Summary
This Phase 2 study is designed to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-038 in adults with complement-mediated kidney diseases.
Official title: A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
45
Start Date
2025-08-28
Completion Date
2028-07
Last Updated
2026-03-02
Healthy Volunteers
No
Interventions
ADX-038 Dose Level 2
siRNA duplex oligonucleotide
ADX-038 Dose Level 1
siRNA duplex oligonucleotide
Locations (12)
ADARx Clinical Site
Shreveport, Louisiana, United States
ADARx Clinical Site
Shelby, Michigan, United States
ADARx Clinical Site
Dakota Dunes, South Dakota, United States
ADARx Clinical Site
Dallas, Texas, United States
ADARx Clinical Site
Houston, Texas, United States
ADARx Clinical Site
Wollongong, New South Wales, Australia
ADARx Clinical Site
Pok Fu Lam, Hong Kong
ADARx Clinical Site
Shatin, Hong Kong
ADARx Clinical Site
Gyeonggi-do, New South Wales, South Korea
ADARx Clinical Site
Seoul, New South Wales, South Korea
ADARx Clinical Site
Cheonan, South Korea
ADARx Clinical Site
Seoul, South Korea